Logistics of Adopting ¹⁷⁷Lu-Vipivotide Tetraxetan Therapy in a Community-Based Hospital Setting

Abstract

Prostate cancer is a leading cause of cancer death in men. Advanced disease may progress to metastatic castration-resistant prostate cancer. In March 2022, ¹⁷⁷Lu-vipivotide tetraxetan was U.S. Food and Drug Administration–approved for patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have previously received other therapies, including androgen deprivation and taxane therapies. Methods: Although preliminary data for ¹⁷⁷Lu-vipivotide tetraxetan has shown extension of overall survival of patients, there is little literature about realistically initiating ¹⁷⁷Lu-vipivotide tetraxetan into non–academic-based clinical practices. Results: This article presents a multidisciplinary practice implementation workflow for ¹⁷⁷Lu-vipivotide tetraxetan. It also highlights the challenges and considerations for initiating such a theranostics practice. Conclusion: The aim of this work is to help nontertiary medical centers improve patient accessibility for beneficial radiopharmaceutical therapies, specifically ¹⁷⁷Lu-vipivotide tetraxetan.